Sanofi, Google’s Verily Enter Diabetes JV To Produce Joined Up Solutions
Executive Summary
Sanofi’s diabetes head says French drug maker’s JV pact with Google’s Verily will combine novel therapies for the condition with cutting edge technologies to produce better focused, outcome-based combinations.
You may also be interested in...
Externally Developed Products Mean Bigger Revenues, But Not In Diabetes
External innovation directly links to commercial success for big pharma, and will continue to do so until 2026, according to a new report by Datamonitor Healthcare.
Future Value Creation Depends On Incorporating Data-Driven Technology, EY Concludes
Biopharmas and other life sciences firms risk getting left behind by technology firms if they don't begin addressing patient needs more directly through data-driven technological advances, such as those to aid clinical development or treatment decisions with real-time patient data.
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Johnson & Johnson and Roche launched the big pharma quarterly reporting season. Next up are Novartis, Lilly, Merck, Bayer, GSK, Bristol-Myers Squibb, Amgen and Sanofi. Scrip offers some key points to watch for.